

## To Study the Effect of Low Dose Aspirin Therapy on Renal Function in Elderly Patients

Vibhash Kumar<sup>1,3,4</sup>, Amit Kishor<sup>2</sup>, Vikash Vashisth<sup>3</sup>, Swati Singh<sup>4</sup>

<sup>1</sup>PG- Student, Department of Medicine, Narayan Medical College and Hospital, Sasaram, Bihar, India

<sup>2</sup>Associate Professor, Department of Medicine, Narayan Medical College and Hospital, Sasaram, Bihar, India

<sup>3</sup>PG- Student, Department of Medicine, Narayan Medical College and Hospital, Sasaram, Bihar, India

<sup>4</sup>PG- Student, Department of Medicine, Narayan Medical College and Hospital, Sasaram, Bihar, India

---

Received: 25-08-2022 / Revised: 20-09-2022 / Accepted: 04-10-2022

Corresponding author: Dr. Amit Kishor

Conflict of interest: Nil

---

### Abstract

**Aim:** The aim of this study to evaluate the low dose aspirin therapy and renal function in elderly patients

**Methods:** This prospective study was carried out in the Department of Medicine, NMCH, Sasaram, Bihar, India. This study employed a cohort of 50 elderly patients (age 60 years) and was comprised of 30 male and 20 female patients at the commencement of the study. The United Nations definition of an elderly person was used.

**Results:** A total of 50 participated in this preliminary study. There were 20 (40%) females and 30 (60%) males with age range between 50–80 years and mean ages of 59.88 years ( $\pm 7.16$ ) and 65.77 years ( $\pm 10.09$ ) for males and females, respectively. 21 (42%) of the patients had more than one diagnosis. Systemic hypertension was the most common diagnosis, accounting for 31 (62%) of cases. Hypertension and diabetes mellitus coexisted in seven (24%) of the study participants. 88% exhibited their basal renal function in stages 1 and 2 based on CrCl. The P-value for all these weekly parameters did not show statistical significance except for the CrCl ( $P = 0.021$ ). The CrCl reduced at week 2, and then increased at week 3, pleateauing before gradually returning to baseline at the sixth week. The mean hemoglobin was  $12.7 \pm 5.7$  g/dL with a range of 7.7–15.7 g/Dl.

**Conclusion:** This study did not show any deleterious effects of short-term, low dose aspirin (75 mg) use on the renal function of elderly patients. This 6-week study was cumbersome for most of the patients, and this precluded the participation of a lot of eligible geriatric patients.

**Keywords:** renal function, aspirin, geriatric patients

---

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

---

### Introduction

Cardiovascular disease (CVD) is the leading cause of death and disease burden in China and worldwide. [1,2] Low-dose

aspirin is the cornerstone of secondary prevention of ASCVD. However, some researchers discovered that low-dose

aspirin could raise SUA by a decrease in uric acid excretion, causing hyperuricemia which is a common clinical condition that can be defined as SUA level  $>420\mu\text{mol/l}$  ( $7\text{mg/dL}$ ) in male or  $>360\mu\text{mol/l}$  ( $6\text{mg/dL}$ ) in female. [3] Numerous evidence [4-6] have suggested the existence of an association between elevated SUA and CVD, traditional cardiovascular risk factors, metabolic syndrome, insulin resistance, chronic kidney disease and heart failure. [7-9] Hyperuricemia is an independent predictor not only of all-cause and cardiovascular mortality, but also of myocardial infarction, stroke and heart failure [10] and it may act as a promoter of renal damage for correlating with lower renal glomerular filtration rate and macroalbuminuria. [11] But there are few studies focusing on the effects of low-dose aspirin treatment for a longer time (used to be no more than 2 weeks) on uric acid and its urinary excretion among Chinese elderly patients. Aspirin, also known as acetylsalicylic acid (ASA), is a medication used to treat pain, fever, or inflammation. Specific inflammatory conditions in which aspirin is used include Kawasaki disease, pericarditis, and rheumatic fever. Aspirin given shortly after a heart attack decreases the risk of death. Aspirin is also used long-term to help prevent heart attacks, ischaemic strokes, and blood clots, in people at high risk. Aspirin may also decrease the risk of certain types of cancer, particularly colorectal cancer. For pain or fever, effects typically begin within 30 minutes. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and works similar to other NSAIDs but also suppresses the normal functioning of platelets. [12] Common side effects include an upset stomach. More significant side effects include stomach ulcers, stomach bleeding, and worsening asthma. Bleeding risk is greater among those who are older, drink alcohol, take other NSAIDs, or are on blood thinners. [13]

Aspirin is not recommended in the last part of pregnancy. It is not generally recommended in children with infections because of the risk of Reye's syndrome. High doses may result in ringing in the ears. The aim of this study to evaluate the effect of low dose aspirin therapy on renal function in elderly patients.

### **Material and methods**

This prospective study was carried out in the Department of Medicine, NMCH, Sasaram, Bihar, India.

This study employed a cohort of 50 elderly patients (age 60 years) and was comprised of 30 male and 20 female patients at the commencement of the study. The United Nations definition of an elderly person was used.<sup>13</sup>

### **Inclusion criteria**

New patients ready to participate and had given consent for the study with various medical conditions including coronary artery disease, ischemic cerebrovascular disease etc. necessitating the use of low dose aspirin for the first time and remained in stable clinical conditions throughout the study were included.

### **Exclusion criteria**

Patients with a past history of any type of previous treatment with aspirin or on continuing aspirin therapy, active peptic ulcer disease, gastrointestinal bleeding, chronic liver disease and kidney disease will not be included

Also, patients enrolled in the study but developed complications during study period will be excluded.

### **Methodology**

Blood and 24 hours urine samples were collected before the first dose of aspirin. Thereafter, aspirin at a dose of 75 mg/day was administered orally after breakfast for 12 weeks Blood and 24-hour urine samples were again collected at end of 6 weeks and 12 weeks

### Sample collection

Subjects will be taught how to collect their 24-hour urine prior to their clinic day when the blood would be collected. After an overnight fast, 10 mL of venous blood will be collected at the ante cubital fossa in the sitting position without stasis; 5 mL of the blood will be put into lithium heparinized bottle, and the remaining 5 mL will be put into a plain bottle. Serum was obtained after clotting, centrifuged at 3500 rpm for 10 minutes, and immediately stored at  $-20^{\circ}\text{C}$  until they were analysed. Sodium and chloride will be analysed using ion selective electrodes, potassium by methods indirect ion specific electrodes, Serum creatinine will be analysed by enzymatic creatinase method, serum urea will be analysed by urease and serum uric acid by uricase method respectively, using Erba EM 200 fully autoanalyzer and EasyLyte analyser. Urinary CrCl and uric acid clearance were evaluated by 24-hour urine collection for CrCl and uric acid clearances.

### Statistical analysis

Each patient's baseline samples at enrolment (before commencing aspirin) served as the control, and subsequent weekly samples were compared. The difference of means from the baseline mean will be determined and compared for statistical significance ( $P \# 0.05$ ) using the

Statistical Package for the Social Sciences version 22.0 software (IBM SPSS Inc, Chicago, IL, USA) in my personal computer.

### Results

A total of 50 participated in this preliminary study. There were 20 (40%) females and 30 (60%) males with age range between 50–80 years and mean ages of 59.88 years ( $\pm 7.16$ ) and 65.77 years ( $\pm 10.09$ ) for males and females, respectively. Table 1 shows the clinical data of the patients.

21 (42%) of the patients had more than one diagnosis. Systemic hypertension was the most common diagnosis, accounting for 31 (62%) of cases. Hypertension and diabetes mellitus coexisted in seven (24%) of the study participants.

Table 2 shows the stages of renal function based on the National Kidney Function/DOQI guideline: 88% exhibited their basal renal function in stages 1 and 2 based on CrCl. The P-value for all these weekly parameters did not show statistical significance except for the CrCl ( $P = 0.021$ ). The CrCl reduced at week 2, and then increased at week 3, plateauing before gradually returning to baseline at the sixth week. The mean hemoglobin was  $12.7 \pm 5.7$  g/dL with a range of 7.7–15.7 g/dL.

**Table 1: Clinical data**

	Number of patients	%
<b>Diagnosis*</b>		
Systemic hypertension	31	62
Congestive cardiac failure	6	12
Diabetes mellitus	12	24
Peripheral artery disease	8	16
Carotid aneurysm	2	4
Ischemic cardiovascular disease	3	6
Obesity	3	6
Parkinson's disease	2	4
Background COPD	5	10
<b>Drugs**</b>		
Diuretics	47	94

Antibenign prostatic hypertrophy (and receptor blocker)	2	4
Antihypertensives		
Excluding thiazides and angiotensin converting enzyme inhibitors	28	56
Digoxin	3	6
Oral hypoglycemic agents	8	16
Insulin	3	6
Angiotensin converting enzyme inhibitors	21	42

**Notes:** \*Some patients had multiple diagnoses; \*\*all the patients were on multiple drugs.

**Table 2: NKF/DOQI classification of patients in this study**

Stage	GFR (mL/min)	CrCl (%)
1	90	28 (56)
2	60–89	16 (32)
3	30–59	6 (12)
4	15–29	–
5	>15	–

## Discussion

This study did not show any significant deterioration effects in renal function in the geriatric patients studied, during or after a 2-week administration of low dose (75 mg) aspirin in all of the investigated parameters. This is not in accordance with previously published. [19-21] Previous studies have shown that low dose aspirin (75–325 mg) in the elderly, even on a short-term basis, had significant effects on renal tubular function. [19-21] Furthermore aspirin (75 mg) per day, administered for 1 week, the uric acid clearance and CrCl reduced. Only the uric acid clearance returned to the baseline 1 week after the discontinuation of aspirin. [19]

The disparity from previous studies noticed in this study may be due to the better baseline renal functions of our patients.

As shown in Table 2, more than 88% of the study subjects had their basal renal function (CrCl, 88%) in stages 1 and 2 of the American National Kidney Foundation criteria, whereas only about 50% (CrCl, 57%) of the patients in the Segal et al[21] study had theirs in the later stages.

There were 20 (40%) females and 30 (60%) males with age range between 50–80 years and mean ages of 59.88 years ( $\pm 7.16$ ) and 65.77 years ( $\pm 10.09$ ) for males and females, respectively. Previous studies used older patients with a mean age of  $80 \pm 9$  years, [21] and an average age of 81 years[20]. Of note, renal functions depreciate with age; [22,23] hence, the basal renal functions of the patients in this study were better than those of other studies. This might have attenuated the renal effects of low dose aspirin.

Only 3 (6%) of the patients in this study were anemic. This is in keeping with the stage of their renal functions. Anemia in chronic kidney disease becomes progressively pronounced from stage 3 onward. [24] Similarly, only 23 (46%) of the patients had hypoalbuminemia.

Previous studies have shown that hypoalbuminemia and anemia potentiate the deleterious effects of low dose aspirin on renal function. [19-21] This current study did not conform to this. This may be due to the very small number of our study patients having either hypoalbuminemia or anemia.

Previous studies have also shown significantly lower CrCl on a concomitant low dose aspirin–diuretic combination.

[25,26] Our finding differs from this observation, as 88% of the patients in this study were on this combination, yet there was no significant lowering of the CrCl. [27] we observed positive statistical significance ( $P \leq 0.021$ ) in the CrCl parameter. The CrCl at week 2 reduced and increased by the third week, plateauing before gradually returning to baseline at the sixth week. We are of the opinion that the multiple drugs aimed at ameliorating the various comorbid conditions in the patients of our study might have acted in synergy with the low dose aspirin to give this favorable increase in CrCl during the study. A larger sample with the application of more advanced statistics is advocated in order to provide a more concrete explanation for this observation. The small sample size is a limitation of this study. The decision to put an elderly patient on low dose aspirin should be based on the basal renal functions and the age of the patient. Caution should be exercised when dealing with those in renal stages 3–5, and when dealing with the very elderly (age 80 years). We also suggest that the 75 mg dose of aspirin should be retained as the antiplatelet of choice in the elderly in developing countries.

### Conclusion

This study did not show any deleterious effects of short-term, low dose aspirin (75 mg) use on the renal function of elderly patients. This 6-week study was cumbersome for most of the patients, and this precluded the participation of a lot of eligible geriatric patients. The small sample size combined with the tasking nature of the study that was conducted in a peculiar setting might have affected the results. We suggest that more studies be conducted in our own environment with a larger sample size, and possibly in a center with a predominant geriatric population.

### Reference

1. Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. *Lancet*. 2016;387(10015):251–272.
2. Mortality GBD. Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;385(9963):117–171.
3. Multidisciplinary Expert Task Force on H, Related D. Chinese multidisciplinary expert consensus on the diagnosis and treatment of hyperuricemia and related diseases. *Chin Med J (Engl)*. 2017;130(20): 2473–2488.
4. Li M, Hu X, Fan Y, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. *Sci Rep*. 2016;6:19520.
5. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. *National Health and Nutrition Examination Survey*. *JAMA*. 2000;283(18):2404–2410.
6. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein Mortality Risk study (AMORIS). *J Intern Med*. 2009;266(6):558–570.
7. Ndrepepa G. Uric acid and cardiovascular disease. *Clin Chim Acta*. 2018;484:150–163.
8. Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric acid and the risks of kidney failure and death in individuals with CKD. *Am J Kidney Dis*. 2018;71(3):362–370.
9. Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. *J Hypertens*. 2015;33(9):1729–1741; discussion 1741.
10. Maloberti A, Giannattasio C, Bombelli M, et al. Hyperuricemia and risk of

- cardiovascular outcomes: the experience of the URRAH (Uric Acid Right for Heart Health) Project. *High Blood Press Cardiovasc Prev.* 2020; 27 (2):121–128.
11. Russo E, Viazzi F, Pontremoli R, et al. Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. *J Nephrol.* 2021.
  12. Patrignani P, Patrono C. (30 August). Aspirin and Cancer. *Journal of the American College of Cardiology.* 2016; 68(9):967-76.
  13. World Health Organization [webpage on the Internet]. Health statistics and health information systems. Definition of an older or elderly person. Proposed working definition of an older person in Africa for the MDS project. Geneva: World Health Organization. Available from: <http://www.who.int/healthinfo/survey/ageingdefnolder/en/index.html>. Accessed January 10, 2012.
  14. Malmstadt HV, Winefordner JD. Determination of chloride in blood serum, plasma, or other biologic fluids by a new rapid precision method. *Clin Chem.* 1959;5(4):284–296.
  15. Haeckel R. Simplified determinations of the “true” creatinine concentration in serum and urine. *J Clin Chem Clin Biochem.* 1980;18(7):385–394.
  16. Fawcett JK, Scott JE. A rapid and precise method for the determination of urea. *J Clin Pathol.* 1960;13:156–159.
  17. Fossati P, Prencipe L, Berti G. Uses of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymatic assay of uric acid in serum and urine. *Clin Chem.* 1980;26(2):227–231.
  18. Doumas BT, Watson WA, Biggs HC. Albumin standards and the measurement of serum albumin with bromocresol green. *Cin Chim Acta.* 1971;31(1):87–96
  19. Caspi D, Lubart E, Graff E, Habet B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. *Arthritis Rheum.* 2000;43(1):103–108.
  20. Segal R, Lubart E, Leibovitz A, et al. Early and late effects of low-dose aspirin on renal function in elderly patients. *Am J Med.* 2003; 115(6):462–466.
  21. Segal R, Lubart E, Leibovitz A, Iaina A, Caspi D. Renal effects of low dose aspirin in elderly patients. *Isr Med Assoc J.* 2006;8(10):679–682.
  22. Schramm A, Jenett M, Gerhardt KH. Changes in kidney function and morphology in the aged. *Z Gerontol.* 1981;14(5):354–369. German.
  23. Godin M, Moulin B, Etienne I, Fillastre JP. Renal aging in man. *Presse Med.* 1992;21(26):1246–1248. French.
  24. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function and anemia: the Third National Health and Nutrition Examination Survey (1988–1994). *Arch Intern Med.* 2002;162(12):1401–1408.
  25. Sweileh WM. Potential adverse effects of a low-dose aspirin-diuretic combination on kidney function. *Int J Clin Pharmacol Ther.* 2007; 45(11):601–605.
  26. Juhlin I, Jönsson BA, Höglund P. Renal effects of aspirin are clearly dose-dependent and are of clinical importance from a dose of 160 mg. *Eur J Heart Fail.* 2008;10(9):892–898.
  27. Onyinye, A. U. ., C, U.-C. H., & A, O. J. Sexual Assault; Our experience at One Stop Shop for Women and Girls, National Obstetric Fistula Centre, Abakaliki, Ebonyi State. South East Nigeria: A retrospective study. *Journal of Medical Research and Health Sciences,* 2022; 5(7): 2118–2124.